Viking Therapeutics Inventory Might Soar 45% Forward Of Key Weight Loss Drug Readout: JPMorgan – Viking Therapeutics (NASDAQ:VKTX)

JPMorgan analyst Hardik Parikh initiated protection on Viking Therapeutics Inc VKTX with an Obese score and a December 2025 value goal of $80, which suggests a possible 45% upside from its present value of $54.65.

On the core of this bullish outlook is Viking’s weight problems drug candidate, oral-2735, which may very well be a major participant within the quickly increasing GLP-1 market.

Oral-2735 Might Be A Recreation Changer

JPMorgan highlights oral-2735’s potential as a extremely aggressive remedy within the GLP-1 market, significantly due to its “spectacular tolerability.”

In keeping with Parikh, Part 1 knowledge on decrease doses already demonstrated aggressive efficacy with only a few gastrointestinal unintended effects.

He additionally famous that “larger dose cohorts may present much more aggressive efficacy” whereas sustaining a standout tolerability profile.

With the U.S. marketplace for GLP-1s projected to succeed in $120 billion by 2030, JPMorgan estimates oral-2735 may seize round 10% of the oral weight problems section, ascribing it a major function within the weight problems remedy panorama. Parikh believes the market has not totally appreciated the potential of oral-2735, making Viking’s inventory poised for a considerable rise.

Learn Additionally: Pretend Ozempic Targets Weight-Loss Market: Solid Batches An Worldwide Concern

Upcoming Catalyst At Weight problems Week

Viking Therapeutics is now beneath JPMorgan’s “optimistic catalyst watch” forward of the Part 1 readout at Weight problems Week in Nov. 2024.

Parikh means that traders must be “lengthy into the upcoming readout for oral-2735.” The info may result in a “substantial up transfer for shares.” Based mostly on latest traits within the weight problems remedy area, Parikh would not be stunned if the inventory sees a soar of 30-60% following the readout.

With oral-2735 anticipated to enter the market in 2030, JPMorgan forecasts U.S. gross sales of $1 billion by 2035. Given the drug’s aggressive profile and favorable tolerability, Viking Therapeutics may play a key function within the booming weight problems market.

For traders, the upcoming knowledge launch may very well be a turning level, with Parikh projecting a major “upside potential” for VKTX inventory because the market begins to acknowledge oral-2735’s potential.

Learn Subsequent:

Picture: Shutterstock